Jean F. Regal, PhD

Department Head, Department of Biomedical Sciences

Jean F. Regal

Contact Info

Office Phone 218-726-8950

Fax 218-726-7906

Office Address:
Department of Biomedical Sciences
313 SMed
1035 University Drive
Duluth, Minnesota 55812

Postdoctoral Appointment-Research Scientist I and Research Fellow, Kidney Disease Institute, New York State Department of Health, Department of Microbiology/Immunology, Albany Medical College

PhD, Pharmacology, University of Minnesota, 1977

BS, Summa cum Laude, University of Minnesota, Biochemistry


Dr. Regal was named the Co-Interim Regional Campus Dean of the University of Minnesota Medical School, Duluth Campus. She became active in this role on April 19, 2021.

Awards & Recognition

University of Minnesota

  • Medical School Carole J. Bland Outstanding Faculty Mentor Award, 2019
  • Linda Larson Faculty Woman of the Year Award, University of Minnesota, Duluth, 2015

University of Minnesota Medical School Duluth

  • Basic Science Teacher of the Year 1986

External Sources

  • Fellow, Academy of Toxicological Sciences- elected, 2011-present
  • Society of the Sigma Xi, Thomas F. Andrews Prize, 1973
  • Minnesota Heart Association Summer Fellowship, 1969

Professional Associations


Research Summary/Interests

The overall goals of my research program involve understanding basic immune mechanisms of cardiopulmonary disease. I have a long-standing interest in the complement system as a mediator of adverse events in disease states such as anaphylaxis, asthma and most currently pregnancy-induced hypertension. These interests have also involved defining mechanisms of pulmonary immunotoxicity of small molecule workplace allergens such as trimellitic anhydride. My research approach involves experimentation at the molecular, biochemical and physiological levels using animal models of disease. Current research projects include:

Pregnancy-induced Hypertension

Preeclampsia and related hypertensive disorders of pregnancy affect ~10% of all pregnancies in the United States, significantly impacting the health of both mother and child. The initiating event of preeclampsia involves impaired blood flow to the placenta and the end result for the mother is high blood pressure and protein in the urine, along with growth restriction in the fetus. During pregnancy, the immune system including the plasma complement system, is tightly regulated to allow fetal survival. In women with preeclampsia the complement system is excessively activated, and our long-term goal is to determine the therapeutic utility of manipulating the complement system to prevent preeclampsia or minimize consequences for the mother and child. We hypothesized that complement system activation and white blood cell recruitment lead to hypertension in the mother and growth restriction in the fetus. Thus, we are manipulating the complement system and white blood cell function in a model of placental ischemia induced high blood pressure to determine the critical mechanisms responsible for the pregnancy complications. Our most recent studies are defining the role of natural antibody and the B lymphocyte in initiating complement activation in vivo, and assessing the importance of endogenous complement regulators in limiting the activation.

Research Funding Grants

Dr. Regal's lab is currently funded through the National Heart Lung and Blood Institute of NIH and the American heart Association. 


See full list of publications at: PubMed

Regal JF, Laule CF, McCutcheon L, Root KM, Lund H, Hashmat S, Mattson DL. The Complement System in Hypertension and Renal Damage in the Dahl SS Rat. In Press Physiological Reports.


Teaching Areas

Chemotherapy of Infection; Anti-inflammatory Drugs; Drugs for Pulmonary Disorders

Mentoring/Advising: undergraduates, graduate & post-doctoral fellows.